eISSN: 1644-4124
ISSN: 1426-3912
Central European Journal of Immunology
Current issue Archive Manuscripts accepted About the journal Special Issues Editorial board Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
Search
2/2014
vol. 39
 
Share:
Send email
Share:
abstract:

Clinical immunology
Recombinant human interleukin receptor antagonist influences serum chemokines in patients with rheumatoid arthritis

Jun Bao
,
Wei Liu
,
Yi-Xiao Bao

(Centr Eur J Immunol 2014; 39 (2): 170–173)
DOI: https://doi.org/10.5114/ceji.2014.43717
Online publish date: 2014/06/27
View full text Get citation
 
PlumX metrics:
Objective: To investigate the serum expressions of chemokines CCL2 and CCL3 in patients with rheumatoid arthritis (RA) who were treated with recombinant human interleukin 1 (IL-1) receptor antagonist (IL-1Ra).

Material and methods: Serum CCL2 and CCL3 were determined using an enzyme-linked immunosorbent assay in 54 active RA patients before and after treatment with IL-1Ra or a placebo, as well as 36 healthy controls.

Results: Compared with the healthy controls, all the 54 RA patients exhibited higher serum CCL2 and CCL3 before and after treatment (p < 0.05). However, patients who had a good response to IL-1Ra treatment had significantly lower mean changes in the serum CCL2 and CCL3 levels from baseline to the last injection than IL-1Ra non-responders (p < 0.01).

Conclusions: CCL2 and CCL3 may be useful efficacy markers of IL-1Ra treatment.
keywords:

arthritis, rheumatoid, chemokines, interleukin-1 receptor antagonist protein, drug therapy
Termedia
About us Contact
Copyright notice Privacy policy Advertising policy Contact us
Quick links
Journals Books eBooks Events
© 2024 Termedia Sp. z o.o.
Developed by Bentus.